Therapeutic Asset Ratings
19,639 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Hormone-Resistant Prostate Cancer
University of Wisconsin, Madison
P2
BB
(66)
Cyclophosphamide
Locally Advanced Malignant Solid Neoplasm
City of Hope Medical Center
P2
BB
(66)
Cyclophosphamide
Ovarian Clear Cell Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(66)
Cyclophosphamide
Ovarian Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(66)
Cyclophosphamide
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
BB
(66)
Cyclophosphamide
Retinoblastoma
Seattle Children's Hospital
P2
BB
(66)
Cyclophosphamide
Stage IV Bladder Cancer AJCC v8
Fred Hutchinson Cancer Center
P2
BB
(66)
Cyclophosphamide
Stage IV Ureter Cancer AJCC v8
Fred Hutchinson Cancer Center
P2
BB
(66)
Cyclophosphamide
Synovial Sarcoma
Zelluna Immunotherapy AS
P2
BB
(66)
CYCLOSPORIN A
Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
P2
BB
(66)
Dalzanemdor
Cognitive Disorder
Supernus Pharmaceuticals, Inc.
P2
BB
(66)
Dasatinib
Malignant Pancreatic Neoplasm
OHSU Knight Cancer Institute
P2
BB
(66)
DEXAMETHASONE
Post-transplant Lymphoproliferative Disorder
Northwestern University
P2
BB
(66)
Docetaxel
Ovarian Neoplasm
Merck Sharp & Dohme LLC
P2
BB
(66)
Durvalumab
Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
P2
BB
(66)
Durvalumab
Estrogen-Receptor Positive Breast Cancer
National Taiwan University Hospital
P2
BB
(66)
Durvalumab
Malignant Pancreatic Neoplasm
Jonsson Comprehensive Cancer Center
P2
BB
(66)
Eloxatin
Bile Duct Cancer
Lisata Therapeutics, Inc.
P2
BB
(66)
Eloxatin
Primary Mediastinal Large B-Cell Lymphoma
City of Hope Medical Center
P2
BB
(66)
Eloxatin
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Genmab
P2
BB
(66)
Eloxatin
Small Lymphocytic Lymphoma
City of Hope Medical Center
P2
BB
(66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Renal Pelvis/Ureter Urothelial Carcinoma
National Cancer Institute (NCI)
P2
BB
(66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urinary Bladder Cancer
Fred Hutchinson Cancer Center
P2
BB
(66)
Epirubicin
Melanoma and Other Malignant Neoplasms of Skin
Institute of Oncology Ljubljana
P2
BB
(66)
Epirubicin
Metastatic Head and Neck Carcinoma
National Cancer Institute (NCI)
P2
BB
(66)
Showing 601 to 625 of 19,639 assets
Previous
Page 25 of 786
Next